We used a proteomic approach to gain insights into the mechanisms of protection at the
protein level by a high n-3:n-6 ratio in the absence and presence of
Tamoxifen. Four groups were treated with 1-methyl-1-nitrosourea (MNU) and fed the following diets with varied n-3:n-6 ratios; group 1 = 1:1; groups 2 and 3 = 10:1 and 25:1, respectively; group 4: (25:1) plus
Tamoxifen (1 mg/kg diet). The plasma from six rats/group was pooled and analyzed with the isobaric tags for relative and absolute quantitation method; 148
proteins were identified with 95% confidence by ProteinPilot 4.0. In plasma of rats fed 10:1, 25:1 n-3:n-6, and 25:1 plus
Tamoxifen, the number of
proteins that met our criteria (P ≤ 0.05, error factor ≤ 2) were 10, 14, and 19
proteins, respectively. Selected
proteins were further validated by Western blotting. Compared to 1:1, both 10:1 and 25:1 diets upregulated
vitamin D binding protein,
gelsolin, and 14-3-3 sigma, reported to have
tumor suppressive effects, whereas alpha-1B-glycoprotein, which has been reported to be elevated in the serum of
breast cancer patients was decreased. Compared to 25:1, the 25:1 plus
Tamoxifen diet downregulated
apolipoprotein E,
haptoglobin, and inter-α-inhibitor H4 heavy chain. Ingenuity pathway analysis determined that the trends of specific
proteins were related to lipid metabolism in the 25:1 n-3:n-6 group, whereas the 25:1 n-3:n-6 plus
Tamoxifen group included
proteins involved in
cancer and
inflammation. Our results show that several
proteins were altered in a manner consistent with
chemoprevention. Such
proteins may serve as
biomarkers to monitor efficacy of n-3 and
Tamoxifen in future clinical
chemoprevention trials.